Skip to content

Differing predictors of resistance to atazanavir/ritonavir or Kaletra identified

Cost of treatment and care becoming sensitive issue for UK as NHS faces spending slow-down

BHIVA: UK HIV patients remained on first combination for almost seven years during early-HAART era

Atazanavir/ritonavir as potent over two years as Kaletra, but has better side-effects profile

HAART reduces AIDS events even when treatment response is poor

CROI: Etravirine (TMC125) and darunavir (TMC114) in treatment-experienced patients

CROI: Merck integrase inhibitor strong in highly treatment-experienced patients

ICAAC: TMC114 shows further promise in second POWER study

Low uptake of T-20 may be caused by doctors misjudging patient attitudes to self-injection